tocilizumab: Clinical Trials

140 trials of tocilizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

102 completed, 10 recruiting, 8 unknown, 7 active not recruiting. 140 Phase 3, 11 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3140Completed 102, Recruiting 10, Unknown 8, Active not recruiting 7, Terminated 7, Not yet recruiting 5, Withdrawn 1
Phase 211Completed 6, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1

Follow tocilizumab: new trials by email Literature Review of tocilizumab trials Research Report on tocilizumab

Trials (filtered) newest first · largest first

All 140 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig
Obrixtamig, Ezabenlimab, Atezolizumab - Advanced Cancer
Phase 3Not yet recruitingBoehringer Ingelheim682027-03-042026-11-10
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis
Phase 3Not yet recruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company922027-02-032026-09-18
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
Anakinra, Tocilizumab, Standard medical treatment - New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus
Phase 3Not yet recruitingYale University4382026-12-012026-08-19
Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE
Tociliuzumab, Placebo - Acute Ischemic Stroke
Phase 2 / Phase 3Not yet recruitingOslo University Hospital1562026-09-212026-10-13
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC3402026-05-182026-11-10
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
Tocilizumab, Placebo - Ischemic Stroke
Phase 3RecruitingCapital Medical University3482026-04-222026-11-03
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab - Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Phase 3RecruitingDuke University4002026-01-092026-10-21
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
Tocilizumab, Placebo - Acute Ischemic Stroke
Phase 3Active not recruitingCapital Medical University6922025-12-052026-10-06
Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis
Tocilizumab, NaCl 0.9% 100ml - Brain Diseases, Ischemic Stroke
Phase 3Not yet recruitingZhujiang Hospital4862025-10-302025-07-28
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
Tocilizumab (RoActemra®, 20 mg/mL)., Placebo (NaCl 0.9%) - Sickle Cell Disease, Acute Chest Syndrome
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris1302025-08-272026-06-24
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
Tocilizumab, Nintedanib, Standard therapy - Systemic Sclerosis, Interstitial Lung Disease
Phase 3RecruitingNational Institute of Geriatrics, Rheumatology and Rehabilitation, Poland862025-07-012026-04-08
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
Rituximab, Tocilizumab, Tofacitinib - Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris422025-06-062026-04-03
Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Tocilizumab, Prednisone - Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Phase 2 / Phase 3Active not recruitingTianjin Medical University General Hospital1022024-07-092026-01-08
Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment
Tocilizumab, NaCl 0.9% 100ml - Interleukin-6, Ischemic Stroke
Phase 2 / Phase 3CompletedSuzhou Municipal Hospital of Anhui Province1082024-02-022024-09-25
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Obinutuzumab, Glofitamab, Rituximab - Lymphoma
Phase 3RecruitingHoffmann-La Roche1822023-10-222026-11-05
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Upadacitinib, Tocilizumab - Juvenile Idiopathic Arthritis
Phase 3RecruitingAbbVie902023-10-022026-09-15
Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
Tocilizumab Injection - Myasthenia Gravis, Generalized
Phase 2 / Phase 3UnknownTang-Du Hospital642023-04-012024-01-22
Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis
Complarate®, Actemra® - Rheumatoid Arthritis
Phase 3CompletedAO GENERIUM4652023-02-132024-07-03
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis
CT-P47 AI (tocilizumab), CT-P47 PFS (tocilizumab) - Rheumatoid Arthritis
Phase 3UnknownCelltrion302023-02-062023-02-16
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Mosunetuzumab, Polatuzumab vedotin, Tocilizumab - Non-Hodgkin Lymphoma
Phase 3Active not recruitingHoffmann-La Roche2082022-04-252026-11-03

Showing 20 of 140. Sign in to see all of them.

Conditions studied

Arthritis, Rheumatoid (73)  ·  Arthritis, Juvenile (14)  ·  COVID-19 (12)  ·  Ischemic Stroke (5)  ·  Scleroderma, Systemic (4)  ·  Giant Cell Arteritis (3)  ·  Stroke (3)  ·  Community-Acquired Pneumonia (2)  ·  Lung Diseases, Interstitial (2)  ·  Pneumonia (2)  ·  Polymyalgia Rheumatica (2)  ·  Spondylitis, Ankylosing (2)  ·  Acute Chest Syndrome (1)  ·  Acute Lung Injury (1)  ·  Anemia, Sickle Cell (1)

Sponsors

Hoffmann-La Roche (74)  ·  Chugai Pharmaceutical (10)  ·  Assistance Publique - Hôpitaux de Paris (6)  ·  Capital Medical University (2)  ·  Genentech, Inc. (2)  ·  JW Pharmaceutical (2)  ·  M Abdur Rahim Medical College and Hospital (2)  ·  Oslo University Hospital (2)  ·  Tianjin Medical University General Hospital (2)  ·  AO GENERIUM (1)  ·  AbbVie (1)  ·  Abderrahmane Mami Hospital (1)  ·  Assistance Publique Hopitaux De Marseille (1)  ·  Assiut University (1)  ·  Beneficência Portuguesa de São Paulo (1)

Countries

France (43)  ·  United States (38)  ·  Spain (32)  ·  Italy (31)  ·  Brazil (26)  ·  Canada (26)  ·  Germany (26)  ·  United Kingdom (26)  ·  Australia (21)  ·  Mexico (20)  ·  Poland (20)  ·  Belgium (19)  ·  China (19)  ·  Netherlands (18)  ·  Argentina (17)

Top investigators

Takahiro Kakehi (8)  ·  Akter Kamal, MD, PhD (2)  ·  Yuji Kimura (2)  ·  Ajay K Nooka (1)  ·  Anne Hege Aamodt (1)  ·  Bart Lambrecht, MD, PhD (1)  ·  Benjamin Terrier, MD, PhD (1)  ·  Chao Zhang, M.D., Ph.D (1)  ·  Chuanjie Wu, M.D. (1)

Results publications

PMID 29244149, PMID 30649524, PMID 22491018, PMID 24429164, PMID 18358927, PMID 23765873, PMID 24634205, PMID 24786929, PMID 27909081, PMID 30824645, PMID 32508063, PMID 32912276, PMID 33294861, PMID 33394942, PMID 34473343, PMID 37489818, PMID 18358926, PMID 18625622, PMID 18821691, PMID 19297346, PMID 20039425, PMID 21360490, PMID 21949007, PMID 22397953, PMID 22562983, PMID 22753773, PMID 22972745, PMID 23252525, PMID 23305631, PMID 23322466, PMID 23945134, PMID 24161161, PMID 24473673, PMID 24834925, PMID 24942540, PMID 25169728, PMID 25504861, PMID 26037777, PMID 26056119, PMID 26511996, PMID 26787505, PMID 27087059, PMID 27156934, PMID 27236390, PMID 27287832, PMID 27564431, PMID 27744141, PMID 27747585, PMID 27889300, PMID 28389552

NIH funding

2009 (7), 2008 (6), 2015 (3), 2016 (3), 2023 (3), 2017 (2), 2019 (2), 2025 (2), P30CA138292 (1)